http://orcid.org/0000-0003-3898-7093
References
- Torres J, Mehandru S, Colombel JF, et al. Crohn's disease. Lancet. 2017;389:1741–1755.
- Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389:1756–1770.
- Pascal V, Pozuelo M, Borruel N, et al. A microbial signature for Crohn's disease. Gut. 2017;66:813–822.
- Palmela C, Chevarin C, Xu Z, et al. Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut. 2018;67:574–587.
- Gecse KB, Vermeire S. Differential diagnosis of IBD: imitations and complications. Lancet Gastroenterol Hepatol. 2018;3:644–653.
- Stauffer W, Abd-Alla M, Ravdin JI. Prevalence and incidence of Entamoeba histolytica infection in South Africa and Egypt. Arch Med Res. 2006;37:266–269.
- Bercu TE, Petri WA, Behm JW. Amebic colitis: new insights into pathogenesis and treatment. Curr Gastroenterol Rep. 2007;9:429–433.
- Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128.
- Peterson K, Singh U, Petri WAJ. Enteric amebiasis. In: Tropical infectious diseases: principles, pathogens and practice, 3rd ed. Philadelphia: Saunders Elsevier; 2011. p. 614–622.
- Weinke T, Friedrich-Janicke B, Hopp P, et al. Prevalence and clinical importance of Entamoeba histolytica in two high-risk groups: travelers returning from the tropics and male homosexuals. J Infect Dis. 1990;161:1029–1031.
- Haque R, Huston CD, Hughes M, et al. Amebiasis. N Engl J Med. 2003;348:1565–1573.
- Stanley SLJ. Amebiasis and Infection with free-living amebas. In: Longo D, Kasper D, Jameon J, et al., editors. Harrison’s Principles of Internal Medicine. 18th ed. The McGraw-Hill Companies, Inc.; 2012.
- Ali IK, Mondal U, Roy S, et al. Evidence for a link between parasite genotype and outcome of infection with Entamoeba histolytica. J Clin Microbiol. 2007;45:285–289.
- Ximenez C, Moran P, Rojas L, et al. Reassessment of the epidemiology of amebiasis: state of the art. Infect Genet Evol. 2009;9:1023–1032.
- Shirley DA, Moonah S. Fulminant Amebic Colitis after Corticosteroid Therapy: a systematic review. PLoS Negl Trop Dis. 2016;10:e0004879
- Ibrahim TM, Iheonunekwu N, Gill V, et al. Differentiating amoebic ulcero-haemorrhagic recto-colitis from idiopathic inflammatory bowel disease: still a diagnostic dilemma. West Indian Med J. 2005;54:210–212.
- Blessmann J, Buss H, Nu PA, et al. Real-time PCR for detection and differentiation of Entamoeba histolytica and Entamoeba dispar in fecal samples. J Clin Microbiol. 2002;40:4413–4417.
- Fotedar R, Stark D, Beebe N, et al. Laboratory diagnostic techniques for Entamoeba species. Clin Microbiol Rev. 2007;20:511–532
- Madison-Antenucci S, Relich RF, Doyle L, et al. Multicenter evaluation of BD max enteric parasite Real-time PCR Assay for detection of Giardia duodenalis, Cryptosporidium hominis, Cryptosporidium parvum, and Entamoeba histolytica. J Clin Microbiol. 2016;54:2681–2688.
- Ali IK. Intestinal amebae. Clin Lab Med. 2015;35:393–422.
- Rayan HZ. Microscopic overdiagnosis of intestinal amoebiasis. J Egypt Soc Parasitol. 2005;35:941–951.
- de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13–27.
- Blazquez S, Zimmer C, Guigon G, et al. Human tumor necrosis factor is a chemoattractant for the parasite Entamoeba histolytica. Infect Immun. 2006;74:1407–1411.
- Lin JY, Chadee K. Macrophage cytotoxicity against Entamoeba histolytica trophozoites is mediated by nitric oxide from L-arginine. J Immunol. 1992;148:3999–4005.
- Zhang Z, Mahajan S, Zhang X, et al. Tumor necrosis factor alpha is a key mediator of gut inflammation seen in amebic colitis in human intestine in the SCID mouse-human intestinal xenograft model of disease. Infect Immun. 2003;71:5355–5359.